HC Wainwright & Co. Reaffirms Buy Rating for Dianthus Therapeutics and Increases Price Target to $47
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain an edge in the markets, aiming for successful trading outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNTH
Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is 59.71 USD with a low forecast of 46.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 53.360
Low
46.00
Averages
59.71
High
72.00
Current: 53.360
Low
46.00
Averages
59.71
High
72.00
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DNTH Options Analysis: $40 Put Contract Offers Attractive Yield Boost
- Put Option Appeal: The $40.00 put option for DNTH has a current bid of $1.10, and if an investor sells-to-open this contract, they commit to buying the stock at $40.00, effectively lowering their cost basis to $38.90, which is approximately a 10% discount from the current price of $44.41, making it attractive for potential buyers.
- Yield Potential: Should the put option expire worthless, it would yield a 2.75% return on cash commitment, or an annualized 15.94%, showcasing the YieldBoost potential that appeals to investors interested in DNTH shares.
- Call Option Returns: The $45.00 call option has a current bid of $3.00, and if an investor buys DNTH shares at $44.41 and sells this call, they could achieve an 8.08% total return if the stock is called away at expiration, highlighting the attractiveness of this strategy.
- Risk Assessment: Current analytical data suggests a 69% chance that the $40.00 put option will expire worthless, while the $45.00 call option has a 45% chance of doing the same, indicating that investors should monitor these probabilities for informed decision-making.
Continue Reading
Dianthus CFO Ryan Savitz Sells 20,000 Shares for $903,600
- Executive Transaction: Dianthus Therapeutics CFO Ryan Savitz exercised 20,000 stock options and sold them immediately for approximately $903,600, indicating a focus on liquidity extraction from vested compensation.
- Ownership Change: Following this transaction, Savitz's direct shareholding dropped to zero, suggesting a potential impact on market perceptions regarding his confidence in the company's future.
- Market Reaction: The sale occurred when the stock price was around $44.71, and despite an impressive 81.16% increase over the past year, this action may raise concerns among investors about insider confidence.
- Financing Context: Dianthus recently raised $288 million by issuing 7.6 million shares to underwriters, aimed at funding clinical development and operations, and Savitz's sale could be interpreted as a reflection of the company's ongoing capital needs.
Continue Reading